Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Jun;71(6):366-73.
doi: 10.1024/0040-5930/a000524.

[Good prescribing practice in the elderly]

[Article in German]
Affiliations
Review

[Good prescribing practice in the elderly]

[Article in German]
Beate Wickop et al. Ther Umsch. 2014 Jun.

Abstract

Elderly patients are the most important target group of pharmacotherapy. Older individuals often suffer from multiple co-morbidities, which often results in polypharmacy. A therapy based on guidelines can be problematic and is only rarely examined in clinical trials of elderly patients. In addition, alterations in pharmacokinetics and pharmacodynamics due to increased age have to be considered. As a result of these changes, the elderly are particularly vulnerable to certain drugs. These drugs are classified as potentially inappropriate medication (PIM) for the elderly because they bear an increased risk of adverse drug events resulting in major safety concerns. Several classifications have been published to identify and avoid PIM. In this article, START/STOPP (Screening Tool to Alert doctors to Right Treatment/Screening Tool of Older Persons' potentially inappropriate Prescriptions), PRISCUS (Latin: time-honoured) as well as the Austrian PIM-list and FORTA (fit for the aged) criteria are discussed and explained in detail. The use of these tools is considered to be potentially useful in improving the quality of drug therapy for elderly people. Further, a regular medication review is recommended. The determination of the renal function, which is often limited in the elderly, resulting in a required dose adjustment of the medication as well as the choice of a low initial dose when starting a new drug in the elderly may also contribute to increased medication safety.

Patienten ab einem Alter von 65 Jahren sind die bedeutendste Zielgruppe der Pharmakotherapie. Die im Alter häufig auftretende Multimorbidität bedingt oft eine Polymedikation. Eine leitliniengerechte Therapie aller Erkrankungen ist problematisch und selten in Studien an älteren Patienten geprüft. Zudem sind im Alter auftretende pharmakokinetische und pharmakodynamische Veränderungen zu beachten. Diese bedingen, dass bestimmte Medikamente für ältere Patienten potentiell inadäquat sind, weil sie ein hohes Risiko für unerwünschte Arzneimittelwirkungen bergen. Zur Identifikation von potentiell inadäquater Medikation wurden mehrere Negativlisten und Screening-Tools entwickelt. Im Artikel werden die START/STOPP-Kriterien, die PRISCUS-Liste, die Österreichische PIM-Liste sowie die FORTA-Einteilung näher erläutert. Der Einsatz dieser Tools kann die Qualität der medikamentösen Therapie im Alter verbessern. Zudem empfiehlt sich ein regelmäßiger Medikationsreview. Die Bestimmung der im Alter meist eingeschränkten Nierenfunktion und eine entsprechende Dosisanpassung der Medikation sowie die Wahl einer niedrigen Einstiegsdosis beim Ansetzen eines neuen Medikamentes bei älteren Patienten können ebenfalls einen Beitrag zur Arzneimitteltherapiesicherheit leisten.

PubMed Disclaimer

MeSH terms

Substances

LinkOut - more resources